Cambridge Investment Research Advisors, Inc. Intellia Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 13,004 shares of NTLA stock, worth $117,036. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,004
Previous 10,397
25.07%
Holding current value
$117,036
Previous $214,000
28.97%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
96.1MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$113 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$91.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$86.4 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$46.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$34.3 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $684M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...